ESMO Recommendations on clinical reporting of genomic test results for solid cancers

Otros/as autores/as

Institut Català de la Salut

[van de Haar J] Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam. [Roepman P] Medical Department, Hartwig Medical Foundation, Amsterdam, The Netherlands. [Andre F] INSERM U981, Gustave Roussy, Villejuif. Department of Cancer Medicine, Gustave Roussy, Villejuif. Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre, France. [Balmaña J, Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Castro E] Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain. [Chakravarty D] Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. [Dienstmann R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic—Central University of Catalonia, Vic, Spain. Oncoclínicas, São Paulo, Brazil

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2024-10-31T07:34:46Z

2024-10-31T07:34:46Z

2024-11



Resumen

Genomics; Next-generation sequencing; Targeted therapies


Genómica; Secuenciación de nueva generación; Terapias dirigidas


Genòmica; Seqüenciació de nova generació; Teràpies dirigides


Background Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers, as well as identifying markers of hereditary cancers. Harmonised approaches to interpret the results of genomic testing are needed to support physicians in their decision making, prevent inequalities in precision medicine and maximise patient benefit from available cancer management options. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group assembled a group of international experts to propose recommendations for preparing clinical genomic reports for solid cancers. These recommendations aim to foster best practices in integrating genomic testing within clinical settings. After review of available evidence, several rounds of surveys and focused discussions were conducted to reach consensus on the recommendation statements. Only consensus recommendations were reported. Recommendation statements were graded in two tiers based on their clinical importance: level A (required to maintain common standards in reporting) and level B (optional but necessary to achieve ideal practice). Results Genomics reports should present key information in a front page(s) followed by supplementary information in one or more appendices. Reports should be structured into sections: (i) patient and sample details; (ii) assay and data analysis characteristics; (iii) sample-specific assay performance and quality control; (iv) genomic alterations and their functional annotation; (v) clinical actionability assessment and matching to potential therapy indications; and (vi) summary of the main findings. Specific recommendations to prepare each of these sections are made. Conclusions We present a set of recommendations aimed at structuring genomics reports to enhance physician comprehension of genomic profiling results for solid cancers. Communication between ordering physicians and professionals reporting genomic data is key to minimise uncertainties and to optimise the impact of genomic tests in patient care.


This project was funded by the European Society for Medical Oncology (no grant number is applicable).

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

Elsevier

Documentos relacionados

Annals of Oncology;35(11)

https://doi.org/10.1016/j.annonc.2024.06.018

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)